Interaction of 5-diazoimidazole-4-carboxamide and alkyl and aryl isocyanates in the dark affords 8-carbamoyl-3-substituted-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-on es. In cold methanol or ethanol, the 3-(2-chloroethyl) derivative 7a decomposes to afford 2-azahypoxanthine (14) and methyl and ethyl N-(2-chloroethyl)carbamates, respectively. Compound 7a has curative activity against L-1210 and P388 leukemia and may act as a prodrug modification of the acyclic triazene 5-[3-(2-chloroethyl)triazen-1-yl]imidazole-4-carboxamide (MCTIC), since it ring opens to form the triazene in aqueous sodium carbonate.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1021/jm00368a016 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Discovery of new imidazotetrazinones with potential to overcome tumor resistance.
Eur J Med Chem
September 2023
Biodiscovery Institute, School of Pharmacy, University of Nottingham, University Park, Nottingham, NG7 2RD, UK.
We describe the design, organic synthesis, and characterization, including X-ray crystallography, of a series of novel analogues of the clinically used antitumor agent temozolomide, together with their in vitro biological evaluation. The work has resulted in the discovery of a new series of anticancer imidazotetrazines that offer the potential to overcome the resistance mounted by tumors against temozolomide. The rationally designed compounds that incorporate a propargyl alkylating moiety and a thiazole ring as isosteric replacement for a carboxamide, are readily synthesized (gram-scale), exhibit defined solid-state structures, and enhanced growth-inhibitory activity against human tumor cell lines, including MGMT-expressing and MMR-deficient lines, molecular features that confer tumor resistance.
View Article and Find Full Text PDFTemozolomide: An Overview of Biological Properties, Drug Delivery Nanosystems, and Analytical Methods.
Curr Pharm Des
September 2022
School of Pharmaceutical Science, Sao Paulo State University (UNESP), Araraquara, Sao Paulo, Brazil.
Temozolomide (TMZ) is an imidazotetrazine prodrug used to treat glioblastoma multiforme. Its physicochemical properties and small size confer the ability to cross the blood-brain barrier. The antitumor activity depends on pH-dependent hydrolysis of the methyldiazonium cation, which is capable of methylating purine bases (O6-guanine; N7-guanine, and N3-adenine) and causing DNA damage and cell death.
View Article and Find Full Text PDFDelivery of Temozolomide and N3-Propargyl Analog to Brain Tumors Using an Apoferritin Nanocage.
ACS Appl Mater Interfaces
March 2020
Faculty of Engineering, University of Nottingham, Nottingham NG7 2RD, U.K.
Glioblastoma multiforme (GBM) is a grade IV astrocytoma, which is the most aggressive form of brain tumor. The standard of care for this disease includes surgery, radiotherapy and temozolomide (TMZ) chemotherapy. Poor accumulation of TMZ at the tumor site, tumor resistance to drug, and dose-limiting bone marrow toxicity eventually reduce the success of this treatment.
View Article and Find Full Text PDFC8-Substituted Imidazotetrazine Analogs Overcome Temozolomide Resistance by Inducing DNA Adducts and DNA Damage.
Front Oncol
June 2019
Medical School, Kunming University of Science and Technology, Kunming, China.
Temozolomide (TMZ) is the standard of care chemotherapeutic agent used in the treatment of glioblastoma multiforme. Cytotoxic -methylguaine lesions formed by TMZ are repaired by -methyl-guanine DNA methyltransferase (MGMT), a DNA repair protein that removes alkyl groups located at the -position of guanine. Response to TMZ requires low MGMT expression and functional mismatch repair.
View Article and Find Full Text PDFTunable Stability of Imidazotetrazines Leads to a Potent Compound for Glioblastoma.
ACS Chem Biol
November 2018
Department of Neurosurgery , Johns Hopkins University School of Medicine, Baltimore , Maryland 21287 , United States.
Even in the era of personalized medicine and immunotherapy, temozolomide (TMZ), a small molecule DNA alkylating agent, remains the standard-of-care for glioblastoma (GBM). TMZ has an unusual mode-of-action, spontaneously converting to its active component via hydrolysis in vivo. While TMZ has been FDA approved for two decades, it provides little benefit to patients whose tumors express the resistance enzyme MGMT and gives rise to systemic toxicity through myelosuppression.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!